DCM
PTLA

Dupont Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Dupont Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,977
Closed -$163K – 1063
2018
Q1 		$163K Hold
4,977
– – ﹤0.01% 832
2017
Q4 		$242K Buy
+4,977
New +$252K 0.01% 776

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ZCI
Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return

Dupont Capital Management's PTLA Position: Q2 2018 in Review

Dupont Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2018, closing a stake of 4,977 shares — an estimated $163K sold.

Dupont Capital Management first reported a position in PTLA in Q4 2017 and held it in 2 quarters. The position peaked at $242K in Q4 2017. 204 funds tracked by Wall St. Rank hold PTLA as of Q2 2018.

  • Dupont Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Dupont Capital Management sold 4,977 Portola Pharmaceuticals, Inc. shares in Q2 2018, an estimated $163K.
  • Dupont Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q4 2017 and held it in 2 quarters.
  • Dupont Capital Management's Portola Pharmaceuticals, Inc. position peaked at $242K in Q4 2017.
  • 204 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2018.

Based on Dupont Capital Management's 13F filing for Q2 2018, filed 30 Jul 2018.